NasdaqGM:ADMABiotechs
ADMA Biologics (ADMA) Margin Compression Challenges Bullish Growth Narratives Heading Into Earnings
ADMA Biologics (ADMA) has capped FY 2025 with fourth quarter revenue of US$139.2 million and basic EPS of US$0.21, while trailing twelve month revenue sits at US$510.2 million and EPS at US$0.62. The company has seen quarterly revenue move from US$117.5 million in Q4 2024 to US$139.2 million in Q4 2025, with basic EPS shifting from US$0.47 to US$0.21 over the same period. This sets up a results season where growth expectations and margin quality are front of mind for investors.
See our full...